-
1 Comment
Dali Pharmaceutical Co., Ltd is currently in a long term downtrend where the price is trading 4.5% below its 200 day moving average.
From a valuation standpoint, the stock is 24.2% cheaper than other stocks from the Healthcare sector with a price to sales ratio of 7.3.
Dali Pharmaceutical Co., Ltd's total revenue sank by 15.0% to $58M since the same quarter in the previous year.
Its net income has increased by 72.5% to $4M since the same quarter in the previous year.
Finally, its free cash flow grew by 78.6% to $-4M since the same quarter in the previous year.
Based on the above factors, Dali Pharmaceutical Co., Ltd gets an overall score of 3/5.
| Exchange | SHG |
|---|---|
| CurrencyCode | CNY |
| ISIN | CNE100002VL4 |
| Sector | Healthcare |
| Industry | Drug Manufacturers - Specialty & Generic |
| Market Cap | 259M |
|---|---|
| PE Ratio | None |
| Target Price | None |
| Beta | 0.08 |
| Dividend Yield | None |
Dali Pharmaceuticalco.,Ltd researches, develops, produces, and sells pharmaceutical products in China. It develops Chinese and Western medicine injection. The company's products include xingnaojing, shenmai, and astragalus injections, as well as citicoline injections. It also has patents, including invention patents and utility models. The company was founded in 1996 and is headquartered in Dali, China.
Learn MoreHere's how to backtest a trading strategy or backtest a portfolio for 603963.SHG using our backtest tool. PyInvesting provides the backtesting software for you to backtest your investment strategy. Our backtest software is written using Python code and allows you to backtest stock, backtest etf, backtest options, backtest crypto and backtest forex online. Our backtesting Python framework is highly robust and gives you a realistic simulation of how your strategy would have performed in the past using backtest data.
© PyInvesting 2025
